Advanced Medicine

Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.

Ravi Nalliah explains his journey from biochemistry and molecular biology student, to chartered accountant, to supply chain CDMO founder.

Here we explore the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.

Researchers seek a way to inactivate CAR-T cells in case of adverse effects.

We announce a new Special Series of articles devoted to advanced medicine.

Cures for all presents a real focus for the next decade – but companies must be rewarded for their work.

A new computational tool could help improve the stability and predictability of ADCs.

Jane Osbourn talks about the potential of the UK's cell and gene therapy space.

"Moving beyond Cas9 may be the secret to reducing CRISPR’s off-target effects," says Garrett Rettig.

Can new tools lower the hurdle of high manufacturing costs for cell and gene therapies?